KPV: Alpha-MSH C-Terminal Fragment

KPV (Lys-Pro-Val) is a tripeptide corresponding to the C-terminal amino acids 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a 13-amino acid peptide derived from proopiomelanocortin (POMC) that plays roles in pigmentation, energy homeostasis, and immune regulation through melanocortin receptors (MC1R-MC5R).

Remarkably, the tripeptide KPV retains the anti-inflammatory activity of full-length alpha-MSH despite lacking the pharmacophore sequence (His-Phe-Arg-Trp, residues 6-9) required for melanocortin receptor binding. This means KPV operates through a receptor-independent mechanism that is distinct from classical melanocortin signaling.

With a molecular weight of only 342.43 Da, KPV is one of the smallest bioactive peptides in active research. Its small size, stability, and potent anti-inflammatory activity in preclinical models have generated considerable research interest, particularly in gastrointestinal and dermatological inflammation models.

KPV's anti-inflammatory mechanism centers on direct inhibition of inflammatory signaling cascades, independent of melanocortin receptors.

**NF-kB pathway inhibition:** The most well-characterized mechanism is KPV's direct inhibition of nuclear factor kappa B (NF-kB) activation. In cell models stimulated with LPS, TNF-alpha, or IL-1beta, KPV reduces nuclear translocation of the p65 subunit of NF-kB, thereby suppressing transcription of pro-inflammatory genes including TNF-alpha, IL-6, IL-8, iNOS, and COX-2. This inhibition occurs at the level of IkB-alpha phosphorylation and degradation, upstream of p65 nuclear entry.

**Intracellular uptake:** Unlike most bioactive peptides that signal through cell-surface receptors, KPV appears to enter cells directly. Studies using fluorescently labeled KPV have demonstrated intracellular accumulation in colonocytes and macrophages. Once inside the cell, KPV may interact directly with components of the NF-kB signaling complex, though the precise molecular target remains under investigation.

**PepT1 transporter:** In intestinal epithelial cells, KPV uptake is facilitated by the peptide transporter PepT1 (SLC15A1), which normally transports dietary di- and tripeptides. This transporter-mediated uptake provides a mechanism for KPV to reach intracellular targets in the gut epithelium and may explain its pronounced activity in gastrointestinal inflammation models.

**Downstream effects:** NF-kB inhibition by KPV leads to reduced production of pro-inflammatory cytokines, decreased expression of adhesion molecules on endothelial cells, and reduced infiltration of inflammatory cells in tissue models.

KPV has been studied in multiple inflammatory models, with the strongest evidence in gastrointestinal and dermatological contexts.

Understanding how KPV relates to its parent molecule alpha-MSH is important for research design.

**Alpha-MSH** (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) signals through melanocortin receptors MC1R-MC5R. Its anti-inflammatory effects are mediated through both receptor-dependent pathways (MC1R on macrophages) and receptor-independent pathways (NF-kB inhibition). It also stimulates melanogenesis via MC1R on melanocytes, affects appetite via MC4R in the hypothalamus, and modulates adrenal function via MC2R.

**KPV** retains only the receptor-independent anti-inflammatory activity. It does not bind melanocortin receptors, does not stimulate melanogenesis, and does not affect appetite or adrenal signaling. This makes KPV a more selective tool for studying the receptor-independent anti-inflammatory mechanisms of the alpha-MSH system.

Additionally, KPV's small size confers practical advantages: it is less expensive to synthesize, more stable in solution, and can be transported by PepT1 in the gut epithelium — a route not available to full-length alpha-MSH.

KPV is straightforward to work with due to its small size and good stability.

**Reconstitution:** Dissolve in sterile water or bacteriostatic water. KPV is highly soluble and dissolves immediately. Stock solutions of 10-50 mg/mL are feasible.

**In-vitro concentrations:** Anti-inflammatory effects in macrophage and epithelial cell models are observed at 1-100 micromolar. For NF-kB inhibition studies, 10-50 micromolar is a common working range. Include LPS (100 ng/mL to 1 mcg/mL) or TNF-alpha (10-50 ng/mL) as the inflammatory stimulus.

**In-vivo protocols:** Published rodent DSS-colitis studies use KPV at 12-120 mcg/day administered orally or rectally. For oral studies, KPV can be incorporated into nanoparticle delivery systems to enhance colonic delivery, though free peptide has also shown efficacy.

**Key assays:** NF-kB activation (p65 nuclear translocation by immunofluorescence or Western blot of nuclear fractions), cytokine production (ELISA for TNF-alpha, IL-6, IL-10), iNOS expression and nitric oxide production (Griess assay), and histological scoring (for in-vivo inflammation models).

**Storage:** Lyophilized KPV is stable at -20°C for up to 18 months. Reconstituted solutions are stable at 2-8°C for 14 days. The tripeptide lacks oxidation-sensitive residues, contributing to its good stability profile.

*All materials are for research use only.*